Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

NCT02414958 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

730

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG: Empagliflozin
DRUG: Empagliflozin
DRUG: Placebo

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]